Skip to main content

Quanterix Wins $733K QTDP Grant to Develop Array-Based Prostate Cancer Test


By Justin Petrone

Quanterix this week said that it has been awarded $733,437 in grants under the Qualifying Therapeutic Discovery Project program. The QTDP program, funded through the US Patient Protection and Affordable Care Act of 2010, supports therapeutic discovery programs.

Cambridge, Mass.-based Quanterix will use the funds to develop its AccuPSA prostate cancer test, which runs on its single molecule array, or SiMoA, platform. The company said it will also use the money to develop tests for Alzheimer's disease and Crohn's disease.

President and CEO David Okrongly in a statement called the SiMoA platform "disruptive" and said the firm aims to create a "new standard in sensitivity, precision, speed, and cost savings for the diagnostics market."

Quanterix touts its AccuPSA test as being more than 1,000 times more sensitive than the most sensitive commercial prostate specific antigen assays, and said the assay is designed to determine which prostate cancer patients will remain cancer-free after surgery and to detect early signs of disease recurrence.

Founded in 2007, Quanterix's technology platform includes arrays of femtoliter-sized reaction vessels, each vessel sized to confine a single molecule of interest. The arrays are formed by etching tens to hundreds of thousands of separate reaction vessels into the end of an optical fiber bundle.

According to the firm, each vessel can be used to trap single molecules, and the optical fiber bundle carries light into and out of each vessel, allowing each well to function as an independent assay for a single molecule.

Quanterix’s system also features a proprietary image-capture device and image-analysis software. Since its inception, the company has positioned its technology for use in molecular diagnostics (BAN 9/9/2008).

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.